Recruiting Erectile Dysfunction Studies in Austin
A Study in Patients With Advanced Cancers
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers....
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygo...
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor proth...
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors ha...
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 adminis...
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related mac...
About Erectile Dysfunction Clinical Trials in Austin
Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.
There are currently 7 erectile dysfunction clinical trials recruiting participants in Austin, TEXAS. These studies are seeking a combined 1,491 participants. Research is being sponsored by BiOneCure Therapeutics Inc., Servier Bio-Innovation LLC, Octapharma and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Erectile Dysfunction Clinical Trials in Austin — FAQ
Are there erectile dysfunction clinical trials in Austin?
Yes, there are 7 erectile dysfunction clinical trials currently recruiting in Austin, TEXAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Austin?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Austin research site will contact you about next steps.
Are clinical trials in Austin free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Austin studies also compensate for your time and travel.
What erectile dysfunction treatments are being tested?
The 7 active trials in Austin are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.
Data updated March 2, 2026 from ClinicalTrials.gov